Functional genomics and cardiovascular drug discovery

Circulation

Volumn 104, Issue 12, 2001, Pages 1441-1446

  Lee, R T ^a  

^a Partners Research Facility   (United States)

Author keywords

Drugs; Genes; Molecular biology

Indexed keywords

CARDIOVASCULAR AGENT; DNA; NATURAL PRODUCT; RNA;

BIOENGINEERING; BIOTECHNOLOGY; CARDIOVASCULAR DISEASE; DISEASE PREDISPOSITION; DNA MICROARRAY; DNA SEQUENCE; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; GENOME; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0035909039     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc3701.097176     Document Type: Review

References (40)

1. William Withering and the purple foxglove: A bicentennial tribute
2. History of drugs for thrombotic disease: Discovery, development, and directions for the future
3. Angiotensin converting enzyme inhibitors: Evolution of a new class of antihypertensive drugs
4. Sequence diversity in 36 candidate genes for cardiovascular disorders
5. Pharmacogenetics and the practice of medicine
6. Drug discovery: A historical perspective
7. A map of human genome sequence variation containing 1.42 million single nucleotide polymorophisms
8. The sequence of the human genome
9. Gene expression analysis by transcript profiling coupled to a gene database query
10. Blood flow and vascular gene expression: Fluid shear stress as a modulator of endothelial phenotype
11. A protein encoded within the Down syndrome critical region is enriched in striated muscles and inhibits calcineurin signaling
12. Identification of differentially expressed genes in cardiac hypertrophy by analysis of expressed sequence tags
13. Catalytic nucleic acids: From lab to applications
14. High-diversity combinational libraries
15. High-throughput screening of historic collections: Observations on file size, biological targets, and file diversity
16. Nonpeptide endothelin antagonists: From lower affinity pyrazol-5-ols to higher affinity pyrazole-5-carboxylic acids
17. Present and future in vitro approaches for drug metabolism
18. Strategies for discovering drugs from previously unexplored natural products
19. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
20. Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators
21. Printing proteins as microarrays for high-throughput function determination
22. Proteomics to study genes and genomes
23. Dilated cardiomyopathy-associated proteins and their presentation in a WWW-accessible two-dimensional gel protein database
24. Selenomethionyl proteins produced for analysis by multiwavelength anomalous diffraction (MAD): A vehicle for direct determination of three-dimensional structure
25. The role of protein structure in genomics
26. Perspectives for vascular genomics
27. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin 1 to angiotensin 1-9
28. Microarray expression profiling identifies genes with altered expression in HDL-deficient mice
29. Vascular MADs: Two novel MAD-related genes selectively inducible by flow in human vascular endothelium
30. Overexpression of eolaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation
31. A spatial approach to transcriptional profiling: Mechanotransduction and the focal origin of atherosclerosis
32. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling
33. Decreased SLIMI expression and increased gelsolin expression in failing human hearts measured by high-density oligonucleotide arrays
34. Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy
35. Altered patterns of gene expression in response to myocardial infarction
36. Application of cDNA microarrays in determining molecular phenotype in cardiac growth, development, and response to injury
37. Genomic circuits and the integrative biology of cardiac diseases
38. Effects of early angiotensin-converting enzyme inhibition on cardiac gene expression after acute myocardial infarction